# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- introduce prolonged nerve blocks
- discuss limitations of conventional local anesthetics
- describe side effects of conventional local anesthetics
- motivate development of new local anesthetic formulations
- introduce tetrodotoxin as alternative
- discuss limitations of tetrodotoxin
- describe efforts to introduce tetrodotoxin into clinical practice
- discuss challenges of encapsulating tetrodotoxin
- summarize need for new approach

## SUMMARY OF THE INVENTION

- introduce conjugates of anesthetic agents and biocompatible polymers
- describe prolonged local anesthesia with decreased toxicity
- explain covalent bonds and hydrolysis of ester bonds
- describe release of anesthetic agent in native form
- introduce PEG as chemical permeation enhancer
- describe formulations of anesthetic-polymer conjugates in PEG200
- introduce site one sodium channel blockers
- describe tunable release of anesthetic agents
- introduce biocompatible polymer backbones
- describe methods of making and using conjugates

## DETAILED DESCRIPTION OF THE INVENTION

### I. Definitions

- define site 1 sodium channel blocker
- define anesthesia and anesthetic agents
- define vasoconstrictor and related terms
- define minimum effective concentration
- define biocompatible and related terms
- define backbone polymer and related terms

### II. Compositions

- introduce tunable release of anesthetics
- describe controllable release of anesthetics
- list exemplary anesthetic agents
- describe conjugation of anesthetic agents to polymers
- introduce amphiphilic polymers
- describe PGS conjugates with hydrophilic polymers
- mention additional active agents and excipients
- motivate anesthetic agents
- describe site 1 sodium channel blockers
- introduce tetrodotoxin
- describe chemical structure of tetrodotoxin
- discuss sources of tetrodotoxin
- introduce phycotoxins
- describe general chemical structure of phycotoxins
- introduce saxitoxin
- describe neosaxitoxin and decarbamoyl saxitoxin
- discuss sources of phycotoxins
- introduce vanilloid receptor subtype 1 agonists
- describe capsaicin and derivatives
- introduce capsaicin
- describe structure of capsaicin
- discuss volatility and solubility of capsaicin
- describe pharmacokinetic half-life of capsaicin
- discuss FDA approval of capsaicin
- describe binding of capsaicin to TRPV1
- discuss safety of capsaicin in animal studies
- introduce capsaicinoids
- describe production of capsaicinoids in pepper plants
- discuss capsaicin biosynthesis
- describe commercial availability of capsaicin
- discuss industrial production of capsaicin
- introduce enzymatic synthesis of capsaicinoids
- describe in vitro chemical synthesis of capsaicinoids
- introduce capsinoid analogs of capsaicin
- describe structural differences between capsaicinoids and capsinoids
- discuss bio-potency of capsiate
- introduce synthetic capsaicinoid and capsinoid analogs
- describe modification of acyl chain lengths and aromatic ring
- introduce polymers for controlled release of anesthetics
- describe conjugates of anesthetics and polymers
- introduce polyester polymers
- describe poly(glycerol sebacate) (PGS)
- discuss biocompatibility and biodegradability of PGS
- introduce other bioresorbable polyesters
- describe poly(glycerol sebacate) (PGS) for tissue engineering
- introduce polymers for tunable hydrophilicity
- describe hydrophilic polymers for controlled release of anesthetics
- introduce poly(alkylene glycol) chains
- describe polyethylene glycol (PEG)
- discuss pegylation of MDNPs
- describe physical properties of MDNPs
- discuss covalent anesthetic-polymer conjugates
- list PEG molecular weights
- describe lipidic component
- introduce covalent anesthetic-polymer conjugates
- specify PEG/mPEG molecular weight range
- describe molar ratio of polyester to PEG
- motivate varying PEG amount and size
- introduce covalent linker moieties
- describe biodegradable covalent linkages
- introduce anesthetic agents and additional active agents
- describe attachment via spacers/linkers
- introduce spacers
- describe spacer functions
- list spacer compounds
- describe spacer terminations
- introduce penetration enhancing excipients
- describe PEG as chemical penetration enhancer
- motivate PEG200 as suitable delivery medium
- describe TDP-TTX/PEG200 formulation
- introduce integrated anesthetic-polymer conjugates and CPE
- describe syringe-injectable formulations
- motivate choice of solvent for syringe-injectable formulations
- describe solubilizing agents
- introduce PEG as solubilizing medium
- define covalent anesthetic conjugates
- formulate conjugates in PEG200
- describe viscoelastic properties
- summarize syringe-injectable formulations
- define covalent anesthetic-polymer conjugates
- describe rate of release
- explain tunable sustained release
- describe PEG-PGS conjugates
- formulate conjugates with additional agents
- describe local anesthetic agents
- describe vasoconstrictors
- describe glucocorticoids
- describe other therapeutic agents
- formulate conjugates with excipients
- describe preservatives
- describe pH adjusting agents
- describe antioxidants
- describe isotonicity agents
- formulate conjugates for parenteral routes
- formulate conjugates for transdermal administration
- formulate conjugates for transmucosal administration
- describe bioerodible inserts
- formulate conjugates in aqueous solution
- formulate conjugates in non-aqueous solvents
- describe lyophilization and rehydration
- describe sterilization methods
- formulate conjugates with proteins
- describe albumin proteins
- provide conjugates in vials
- describe vial sizes
- describe dosage forms

### III. Methods of Use

- provide methods of using covalent anesthetic-polymer conjugates
- contact tissue surrounding nerves with conjugates to decrease sensory activity
- prolong blockade of Site One Sodium Channels with minimal toxicity
- bind to or inhibit cell-surface receptors associated with sensory nerve activity
- block ion channels, such as Site One Sodium Channels or TRPV1 receptor
- administer TTX to decrease or inhibit sensory activity in nerves
- release anesthetic agent in a physiologically active state
- provide effective nerve blockade for prolonged periods
- do not give rise to vasoconstriction
- formulate conjugates for release over a period of time
- administer safe amounts of anesthetic agent
- reduce toxicity
- provide prolonged nerve blockade from TTX
- release anesthetic agents in a native form
- provide methods for treating or preventing pain
- administer conjugates to reduce or inhibit sensory and/or motor function
- delay onset of pain, such as nociceptive and/or neuropathic pain
- identify subjects in need of pain relief
- administer conjugates in combination with additional active agents
- co-administer TTX-PGS-PEG and/or TTX-PGS with other agents
- administer conjugates via injection or implantation
- determine dosage based on body weight
- calculate minimum effective concentration
- prepare dosage units for use in a volume ranging from 0.1 ml to 120 ml
- prepare conjugates with concentrations between 0.01% and 5% (w/v)
- administer conjugates via regional block or infiltration
- treat many conditions where anesthetic formulations can be administered
- prevent or reduce pain associated with surgical procedures
- provide prolonged duration of anesthesia in the eye or ocular cavity
- prevent, reduce or inhibit sensory and/or motor function in peripheral nerves
- treat chronic pain associated with diseases or disorders
- calculate total dosage and rate of release
- determine effective dosages and volumes for treatment of humans

### IV. Formulations and Methods of Making

- determine effective dosages and volumes for treatment of humans
- synthesize TDP polymers via Steglich esterification reaction
- covalently conjugate TTX with TDP polymer
- achieve controlled release of TTX via hydrolysis of ester bonds
- tune hydrophilicity of final copolymers by adding PEG
- synthesize PGS-PEG-TTX conjugates in a three-step reaction
- add glycerol to form a block copolymer of PGS-PEG
- obtain PGS-PEG-TTX conjugates via Steglich esterification
- make syringe-injectable formulations
- provide examples of the present invention

## EXAMPLES

### Example 1: Conjugates of Anesthetic with Amphiphilic Polymers and PEG

- design conjugate of poly(glycerol sebacate) (PGS), PEG and TTX
- list materials
- synthesize TDP polymers
- describe Steglich esterification
- synthesize TDP-drug conjugates
- describe synthesis of TDP-drug conjugates
- synthesize TgD8-isocyanate
- describe synthesis of TgD8-isocyanate
- synthesize TgD8-TTX urethane
- describe synthesis of TgD8-TTX urethane
- describe contact angle procedure
- describe 1H NMR measurements
- describe FTIR measurements
- describe molecular weight measurement
- describe in vitro degradation of polymers
- describe cell culture
- describe cell viability
- describe equilibrium solubility method
- describe TTX solubility in DMSO and DMF
- describe TTX solubility in DCM
- describe degree of drug binding measurement
- describe in vitro drug release
- introduce example 1
- describe drug release and mass loss studies
- detail LC-MS instrumentation and conditions
- outline solvent evaporation method
- describe rheological test
- introduce animal studies
- detail injection procedure
- describe testing of nerve blockade
- outline confocal imaging
- describe IVIS imaging
- detail tissue harvesting and histology
- describe scoring of muscle samples
- outline statistics
- introduce results
- describe synthesis of TDP polymers
- detail characterization of TDP polymers
- describe hydrophilicity of TDP polymers
- outline in vitro degradation of polymers
- introduce cytotoxicity
- describe synthesis of TDP-TTX conjugates
- detail Steglich esterification reactions
- describe challenges of TTX conjugation
- outline degree of binding of TTX to TDP
- describe characterization of TDP-TTX conjugates
- detail FTIR spectroscopy
- describe absorption peaks
- outline presence of TTX
- conclude characterization of TDP-TTX conjugates

### Example 2: TTX-PGS/PEG Provides Long-Duration In Vitro Drug Release without Cytotoxicity

- study release kinetics of TDP-TTX conjugates
- confirm TTX release in native form using HPLC and LC-MS
- investigate TTX release half-time
- show fphil of TDP polymers determines TTX release rate
- demonstrate near linear TTX release profile at lower fphil
- confirm TTX release dependent on ester bond cleavage
- study in vitro drug release and degradation of PGS-PEG-TTX conjugates
- show tunable sustained release of TTX and dexamethasone

### Example 3: Fabrication of Syringe-Injectable Formulation

- prepare injectable solutions and suspensions
- characterize rheology of TDP-TTX/PEG200 formulations
- show syringe-injectability of TDP-TTX/PEG200 formulations

### Example 4: TDP-TTX Conjugates Induce Sciatic Nerve Blockade In Vivo

- study effect of TTX dose on nerve blockade
- show dose-dependent increase in nerve block duration
- demonstrate systemic toxicity of free TTX
- show improved nerve block duration with PEG200
- study nerve block duration with TgD8-TTX/PEG200
- show prolonged nerve block duration with TgD8-TTX/PEG200
- investigate motor block duration
- show CPE-like effect of PEG200
- study fluorescein sodium as a proxy for TTX
- demonstrate PEG200 as a chemical permeation enhancer
- show inactivity of TTX bound to polymer
- study TgD8-TTX/PEG200 diluted with PBS
- exclude CPE effect of PEG200
- confirm slow release of TTX from TgD8-TTX

### Example 5: fphil Effects Toxicity and Efficacy of Conjugated TTX

- study effect of fphil on toxicity and efficacy of conjugated TTX
- show increased systemic toxicity with higher fphil
- demonstrate increased efficacy with higher fphil
- study effect of fphil on mortality rate
- show effect of fphil on block duration

### Example 7: TDP-TTX Conjugates do not Illicit a Tissue Reaction

- study tissue reaction to TDP-TTX conjugates
- show no significant myotoxicity and inflammation
- demonstrate normal nerve histology

### Example 8: PGS-PEG-TTX Conjugates Provide a Universal Therapeutic Drug Platform for all Alcoholic or Carboxylic Acid Drugs

- conjugate capsaicin into PGS-PEG copolymers
- study release of capsaicin from PGS-PEG conjugates
- demonstrate in vivo nerve blockade with PGS-PEG1000-capsaicin-2
- show potential of PGS-PEG-TTX conjugates for large animals

## SUMMARY

- synthesize TDP polymers
- describe degradability and biocompatibility
- synthesize TDP polymers with various fphil
- characterize surface and bulk properties
- conjugate TTX with TDP polymer
- describe controlled release of TTX
- confirm CPE function of PEG200
- describe TDP-TTX/PEG200 formulation
- establish in vivo efficacy and safety
- discuss applicability in large animals
- summarize delivery system design

